Article Text

Download PDFPDF

P097 Preliminary experience with ihtOBTURA®: a novel non-adhesive liquid embolic agent, with post embolization loss of radiopacity, for the endovascular treatment of brain arteriovenous malformations. claridad study
Free
  1. Juan Carlos Llibre Guerra
  1. Hospital Universitario de Salamanca, Instituto de neurología y Neurocirugía. La Habana. Cuba, Spain

Abstract

Introduction ihtOBTURA® (IBERHOSPITEX, Llica de Ball, Spain) is a revolutionary non-adhesive liquid embolic agent, composed by EVOH copolymer and an iodinated compound, dissolved in DMSO

Aim of Study To report a Preliminary Experience with ihtOBTURA®: A Novel Non-Adhesive Liquid Embolic Agent, with post embolization loss of radiopacity, for the Endovascular Treatment of Brain Arteriovenous Malformations

Methods We performed a prospective longitudinal single center study, from November 10, 2021, to September 10, 2022. 42 consecutive patients with brain AVMs, were treated by endovascular way. A total of 102 endovascular procedures were performed with ihtOBTURA®. There were 23 males and 19 females with a mean age of 37.38 years. The most common clinical presentation was intracranial hemorrhage in 35 (83.33%) patients. According to the Spetzler-Martin scale, 25 (59,52%) AVMs were grades IV; 13 (30,95%) AVMs, grade III; and 4 (9,52) AVMs, grades II

Results Complete occlusion was achieved in 26/28 patients (93%) during the study interval, and in 61.90% (26/42) in the entire patient cohort. The 14 remaining patients are scheduled for further EVT. Stability of angiographic occlusion was confirmed in all 26 patients by a control angiogram at 6 months. Mean volume reduction was 80,79% per patients. whereas an average of 7.2 mL of ihtOBTURA® was used per patient. Disabling Permanent Neurological Deficits included 1 case of postinterventional hemorrhage and there were 1 procedure-related death.

Conclusion ihtOBTURA® is a safe and effective new non-adhesive liquid embolic agent, with innovative properties that can improve results on AVMs treatment.

Disclosure of Interest no.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.